GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » Price-to-Owner-Earnings

Aevi Genomic Medicine (Aevi Genomic Medicine) Price-to-Owner-Earnings : (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine Price-to-Owner-Earnings?

As of today (2024-04-28), Aevi Genomic Medicine's share price is $0.1659. Aevi Genomic Medicine does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Aevi Genomic Medicine's Price-to-Owner-Earnings or its related term are showing as below:


GNMX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), Aevi Genomic Medicine's share price is $0.1659. Aevi Genomic Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.29. Therefore, Aevi Genomic Medicine's PE Ratio for today is At Loss.

As of today (2024-04-28), Aevi Genomic Medicine's share price is $0.1659. Aevi Genomic Medicine's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.29. Therefore, Aevi Genomic Medicine's PE Ratio without NRI for today is At Loss.


Aevi Genomic Medicine Price-to-Owner-Earnings Historical Data

The historical data trend for Aevi Genomic Medicine's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine Price-to-Owner-Earnings Chart

Aevi Genomic Medicine Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aevi Genomic Medicine Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aevi Genomic Medicine's Price-to-Owner-Earnings

For the Biotechnology subindustry, Aevi Genomic Medicine's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aevi Genomic Medicine's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's Price-to-Owner-Earnings falls into.



Aevi Genomic Medicine Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aevi Genomic Medicine's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1659/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aevi Genomic Medicine  (NAS:GNMX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aevi Genomic Medicine Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.
Executives
Michael F Cola director, officer: Chief Executive Officer 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil officer: Chief Scientific Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca 10 percent owner 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper officer: CFO & Corporate Secretary C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum officer: Chief Legal Officer C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman officer: Chief Financial Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio officer: Chief Operating Officer 435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087

Aevi Genomic Medicine (Aevi Genomic Medicine) Headlines